Biotts has been granted a primary United States patent for its MTC-Y™ transdermal carrier technology. US Patent No. 12,478,679 B2 was issued by the USPTO on 25 November 2025.
MTC-Y is the proprietary carrier system behind Biotts’ transdermal formulations. Unlike conventional transdermal technologies, it can transport large molecules — including peptides and proteins such as insulin — through the skin into the bloodstream, without breaking the skin surface. To date, MTC-Y has been applied across a growing pipeline of drug candidates, including a completed Phase 1 clinical study for a transdermal dapagliflozin patch, proof-of-concept results for transdermal insulin and semaglutide, and comparative pharmacokinetic studies in local anaesthesia.
The patent, filed via PCT in January 2020, covers the pharmaceutical carrier and compositions based on it. This US grant follows existing patent protection in Poland and Canada, and represents an important step for Biotts as the company advances its pipeline toward further clinical development.
For questions about our technology or collaboration opportunities, contact us at service@biotts.com.